Thromb Haemost 2004; 92(06): 1411-1419
DOI: 10.1160/TH03-10-0649
Wound Healing and Inflammation/Infection
Schattauer GmbH

Polymorphonuclear leukocyte and monocyte activation induced by plasma from patients with heparin-induced thrombocytopenia in whole blood

Mahnouch Khairy
1   INSERM U428, Faculté des Sciences Pharmaceutiques et Biologiques, Université Paris V, Paris, France
2   Laboratoire d’hématologie, Faculté de Pharmacie (Université Paris XI), Châtenay-Malabry, France
,
Dominique Lasne
1   INSERM U428, Faculté des Sciences Pharmaceutiques et Biologiques, Université Paris V, Paris, France
,
Aymeric Amelot
1   INSERM U428, Faculté des Sciences Pharmaceutiques et Biologiques, Université Paris V, Paris, France
,
Malvina Crespin
1   INSERM U428, Faculté des Sciences Pharmaceutiques et Biologiques, Université Paris V, Paris, France
,
Francine Rendu
3   CNRS UMR 7131, Centre de prévention des maladies cardiovasculaires, Hôpital Broussais, Paris, France
,
Martine Aiach
1   INSERM U428, Faculté des Sciences Pharmaceutiques et Biologiques, Université Paris V, Paris, France
,
Christilla Bachelot-Loza
1   INSERM U428, Faculté des Sciences Pharmaceutiques et Biologiques, Université Paris V, Paris, France
› Author Affiliations
Financial support: This study was supported by grants from the French research ministry, the French Society of Haematology, and Sanofi-Synthélabo.
Further Information

Publication History

Received 26 October 2003

Accepted after revision 13 September 2004

Publication Date:
04 December 2017 (online)

Summary

Heparin-induced thrombocytopenia (HIT), a severe complication of heparin therapy, results from platelet activation by heparin-dependent antibodies. Previously, we have shown that plasma from patients with HIT (HIT plasma) induces leukocyteplatelet aggregation in blood. In this report, we examined leukocyte activation by HIT plasma and the contribution of heparin and platelets to this activation, in whole blood. Degranulation of leukocytes from HIT patients was evaluated as a leukocyte activation marker. We showed that polymorphonuclear leukocytes (PMN) and monocytes were the leukocyte subpopulations involved in platelet-leukocyte aggregation induced by HIT plasma in healthy donor blood. PMN and monocyte activation, reflected by increased surface expression of the CD11b adhesion molecule, was induced by HIT plasma in a heparin-dependent manner. The CD11b increase induced by HIT plasma was observed on PMN only when they were associated with platelets. Moreover, the increased CD11b expression on monocytes and PMN correlated strongly with the degree of platelet adhesion to these cells. Degranulation of leukocytes from HIT patients and control subjects (non-HIT heparin-treated patients and healthy subjects) was evaluated in vivo by measuring the plasma myeloperoxidase concentration. HIT plasma contained higher myeloperoxidase concentrations than control plasma, suggesting leukocyte degranulation during HIT. In conclusion, this study provides the first evidence that PMN activation is induced by HIT plasma. HIT plasma induced PMN and monocyte activation in a heparin-dependent manner. In whole blood, platelet association with monocytes and PMN, and the activation of these leukocytes by HIT plasma were interrelated. Finally, leukocyte degranulation could be involved in HIT physiopathology.

 
  • References

  • 1 Chong BH. Heparin-induced thrombocytopenia. Br J Haematol 1995; 89: 431-9.
  • 2 Warkentin TE, Chong BH, Greinacher A. Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost 1998; 79: 1-7.
  • 3 Warkentin TE, Greinacher A. Heparin-Induced Thrombocytopenia. New York: Marcel Deckker; 2000
  • 4 Chong BH, Pitney WR, Castaldi PA. Heparininduced thrombocytopenia: association of thrombotic complications with heparin-dependent IgG antibody that induces thromboxane synthesis in platelet aggregation. Lancet 1982; 02: 1246-9.
  • 5 Kelton JG, Sheridan D, Santos A. et al. Heparin-induced thrombocytopenia: laboratory studies. Blood 1988; 72: 925-30.
  • 6 Amiral J, Bridey F, Dreyfus M. et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 1992; 68: 95-6.
  • 7 Greinacher A, Potzsch B, Amiral J. et al. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost 1994; 71: 247-51.
  • 8 Kelton JG, Smith JW, Warkentin TE. et al. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood 1994; 83: 3232-9.
  • 9 Visentin GP, Ford SE, Scott JP. et al. Antibodies from patients with heparininduced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 1994; 93: 81-8.
  • 10 Visentin GP. Heparin-induced thrombocytopenia: molecular pathogenesis. Thromb Haemost 1999; 82: 448-56.
  • 11 Chong BH, Fawaz I, Chesterman CN. et al. Heparin-induced thrombocytopenia: mechanism of interaction of the heparin-dependent antibody with platelets. Br J Haematol 1989; 73: 235-40.
  • 12 Newman PM, Chong BH. Heparin-induced thrombocytopenia: new evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation. Blood 2000; 96: 182-7.
  • 13 Cines DB, Tomaski A, Tannenbaum S. Immune endothelial-cell injury in heparinassociated thrombocytopenia. N Engl J Med 1987; 316: 581-9.
  • 14 Pouplard C, Iochmann S, Renard B. et al. Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparininduced thrombocytopenia. Blood 2001; 97: 3300-2.
  • 15 Arepally GM, Mayer IM. Antibodies from patients with heparin-induced thrombocytopenia stimulate monocytic cells to express tissue factor and secrete interleukin-8. Blood 2001; 98: 1252-4.
  • 16 Khairy M, Lasne D, Brohard-Bohn B. et al. A new approach in the study of the molecular and cellular events implicated in heparininduced thrombocytopenia. Formation of leukocyte-platelet aggregates. Thromb Haemost 2001; 85: 1090-6.
  • 17 Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood 1986; 67: 27-30.
  • 18 Bachelot-Loza C, Saffroy R, Lasne D. et al. Importance of the FcgammaRIIa-Arg/His-131 polymorphism in heparin-induced thrombocytopenia diagnosis. Thromb Haemost 1998; 79: 523-8.
  • 19 Rinder HM, Bonan JL, Rinder CS. et al. Activated and unactivated platelet adhesion to monocytes and neutrophils. Blood 1991; 78: 1760-9.
  • 20 Jungi TW, Spycher MO, Nydegger UE. et al. Platelet-leukocyte interaction: selective binding of thrombin-stimulated platelets to human monocytes, polymorphonuclear leukocytes, and related cell lines. Blood 1986; 67: 629-36.
  • 21 de Bruijne-Admiraal LG, Modderman PW, Von dem Borne AE. et al. P-selectin mediates Ca(2+)-dependent adhesion of activated platelets to many different types of leukocytes: detection by flow cytometry. Blood 1992; 80: 134-42.
  • 22 Rinder HM, Bonan JL, Rinder CS. et al. Dynamics of leukocyte-platelet adhesion in whole blood. Blood 1991; 78: 1730-7.
  • 23 Rinder CS, Bonan JL, Rinder HM. et al. Cardiopulmonary bypass induces leukocyteplatelet adhesion. Blood 1992; 79: 1201-5.
  • 24 Michelson AD, Barnard MR, Krueger LA. et al. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation 2001; 104: 1533-7.
  • 25 Warkentin TE, Hayward CP, Boshkov LK. et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 1994; 84: 3691-9.
  • 26 Hughes M, Hayward CP, Warkentin TE. et al. Morphological analysis of microparticle generation in heparin-induced thrombocytopenia. Blood 2000; 96: 188-94.
  • 27 Kuijpers TW, Tool AT, van der Schoot CE. et al. Membrane surface antigen expression on neutrophils: a reappraisal of the use of surface markers for neutrophil activation. Blood 1991; 78: 1105-11.
  • 28 Lundahl J, Hallden G, Skold CM. Human blood monocytes, but not alveolar macrophages, reveal increased CD11b/CD18 expression and adhesion properties upon receptor-dependent activation. Eur Respir J 1996; 09: 1188-94.
  • 29 Sengelov H, Kjeldsen L, Diamond MS. et al. Subcellular localization and dynamics of Mac-1 (alpha m beta 2) in human neutrophils. J Clin Invest 1993; 92: 1467-76.
  • 30 Borregaard N, Kjeldsen L, Sengelov H. et al. Changes in subcellular localization and surface expression of L-selectin, alkaline phosphatase, and Mac-1 in human neutrophils during stimulation with inflammatory mediators. J Leukoc Biol 1994; 56: 80-7.
  • 31 de Gaetano G, Cerletti C, Evangelista V. Recent advances in platelet-polymorphonuclear leukocyte interaction. Haemostasis 1999; 29: 41-9.
  • 32 Barry OP, FitzGerald GA. Mechanisms of cellular activation by platelet microparticles. Thromb Haemost 1999; 82: 794-800.
  • 33 Celi A, Pellegrini G, Lorenzet R. et al. P-selectin induces the expression of tissue factor on monocytes. Proc Natl Acad Sci U S A 1994; 91: 8767-71.
  • 34 Amirkhosravi A, Alexander M, May K. et al. The importance of platelets in the expression of monocyte tissue factor antigen measured by a new whole blood flow cytometric assay. Thromb Haemost 1996; 75: 87-95.
  • 35 Lindmark E, Tenno T, Siegbahn A. Role of platelet P-selectin and CD40 ligand in the induction of monocytic tissue factor expression. Arterioscler Thromb Vasc Biol 2000; 20: 2322-8.
  • 36 Peters MJ, Dixon G, Kotowicz KT. et al. Circulating platelet-neutrophil complexes represent a subpopulation of activated neutrophils primed for adhesion, phagocytosis and intracellular killing. Br J Haematol 1999; 106: 391-9.
  • 37 Evangelista V, Manarini S, Sideri R. et al. Platelet/polymorphonuclear leukocyte interaction: P-selectin triggers protein-tyrosine phosphorylation-dependent CD11b/CD18 adhesion: role of PSGL-1 as a signaling molecule. Blood 1999; 93: 876-85.
  • 38 Li N, Hu H, Lindqvist M. et al. Platelet-leukocyte cross talk in whole blood. Arterioscler Thromb Vasc Biol 2000; 20: 2702-8.
  • 39 Neumann FJ, Zohlnhofer D, Fakhoury L. et al. Effect of glycoprotein IIb/IIIa receptor blockade on platelet-leukocyte interaction and surface expression of the leukocyte integrin Mac-1 in acute myocardial infarction. J Am Coll Cardiol 1999; 34: 1420-6.
  • 40 Lorant DE, McEver RP, McIntyre TM. et al. Activation of polymorphonuclear leukocytes reduces their adhesion to P-selectin and causes redistribution of ligands for P-selectin on their surfaces. J Clin Invest 1995; 96: 171-82.
  • 41 Rinder HM, Tracey JL, Rinder CS. et al. Neutrophil but not monocyte activation inhibits P-selectin-mediated platelet adhesion. Thromb Haemost 1994; 72: 750-6.
  • 42 Ott I, Neumann FJ, Gawaz M. et al. Increased neutrophil-platelet adhesion in patients with unstable angina. Circulation 1996; 94: 1239-46.
  • 43 Pidard D, Si-Tahar M, Chignard M. Neutrophil-Platelet interactions. In: Platelet, Thrombosis and the vessel Wall, Advances In Vascular Biology Book Series. Berndt M, Vadas M, Harlan J. eds. Amsterdam: Harwood Academic Publishers; 2000: 189-207.
  • 44 Sheikh S, Nash GB. Continuous activation and deactivation of integrin CD11b/CD18 during de novo expression enables rolling neutrophils to immobilize on platelets. Blood 1996; 87: 5040-50.
  • 45 McEver RP. Adhesive interactions of leukocytes, platelets, and the vessel wall during hemostasis and inflammation. Thromb Haemost 2001; 86: 746-56.
  • 46 Faymonville ME, Pincemail J, Duchateau J. et al. Myeloperoxidase and elastase as markers of leukocyte activation during cardiopulmonary bypass in humans. J Thorac Cardiovasc Surg 1991; 102: 309-17.
  • 47 Clark RA, Klebanoff SJ. Neutrophil-platelet interaction mediated by myeloperoxidase and hydrogen peroxide. J Immunol 1980; 124: 399-405.
  • 48 Siminiak T, Flores NA, Sheridan DJ. Neutrophil interactions with endothelium and platelets: possible role in the development of cardiovascular injury. Eur Heart J 1995; 16: 160-70.